TAK - What's Winning in 2022? 3 Stocks That Are Doing Fine
It's been an ugly year in the stock market in 2022, and most investors are deep in the red. But there's always a winner somewhere. Right now healthcare is seeing a lot of bright spots.
For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration (FDA) approval, and that stock has shot higher with a 30% gain this year. Will Axsome Therapeutics (NASDAQ: AXSM) be the next stock to pop? Its valuation recently jumped 52% in a single day. And Japan's largest drug company, Takeda (NYSE: TAK) , is significantly outperforming the American market while paying a nice dividend. Here's why our roundtable is bullish on these three names for 2022.
Patrick Bafuma (Immunocore): Forget about doing just fine -- Immunocore is crushing it, up over 29% year to date. Since its first drug, Kimmtrak, was approved earlier this year for a rare form of eye cancer called uveal melanoma, this biotech has been off to the races. Plus, with potential label expansion and multiple drugs in its pipeline, this biotech could reward investors for years to come.
For further details see:
What's Winning in 2022? 3 Stocks That Are Doing Fine